BioSpace News Archive

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

FDA external advisors will meet to consider Pfizer and BioNTech data in support of booster shots. The two companies also expect to file for Vaccine Authorization for children in the coming months.

The FDA’s IND approval sets the stage for the very first Phase I/II trial to evaluate EBT-101 as a functional cure for chronic HIV based on the endpoints of safety, tolerability, and efficacy.

NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML).

Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 400,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.

Medexus Pharmaceuticals Inc. today held its annual and special meeting of shareholders virtually.

Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, October 19th to review third-quarter results.

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. today announced positive interim results from the pivotal study “JUPITER-06” (NCT03829969), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with chemotherapy as a first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Novavax, Inc. (Nasdaq: NVAX), today announced its participation in a newly expanded Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 3 (Com-COV3), led by the University of Oxford and funded by the UK Vaccines Taskforce (VTF) and the National Institute for Health Research (NIHR).

Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement with Eyenovia, Inc. (NASDAQ: EYEN) to include a third asset, MydCombi™, for development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.